Ownership history in Bridgefront Capital, LLC · 7 quarters on record
This page tracks every 13F SEC filing in which Bridgefront Capital, LLC reported a position in BIOCRYST PHARMACEUTICALS INC (BCRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 23,650 | -19,329 | -45.0% | 0.05% | $180K | $7.59 |
| 2025 Q2 | ADDED | 42,979 | +9,853 | +29.7% | 0.10% | $385K | $8.96 |
| 2024 Q3 | ADDED | 33,126 | +20,212 | +156.5% | 0.10% | $252K | $7.60 |
| 2024 Q2 | REDUCED | 12,914 | -3,409 | -20.9% | 0.03% | $80K | $6.18 |
| 2023 Q3 | REDUCED | 16,323 | -3,979 | -19.6% | 0.08% | $116K | $7.08 |
| 2023 Q2 | ADDED | 20,302 | +274 | +1.4% | 0.08% | $143K | $7.04 |
| 2021 Q1 | INITIATED | 20,028 | — | — | 0.06% | $204K | $10.17 |
As of 2025 Q4 — sorted by position size